Avadel Pharmaceuticals AVDL Stock
Avadel Pharmaceuticals Price Chart
Avadel Pharmaceuticals AVDL Financial and Trading Overview
| Avadel Pharmaceuticals stock price | 21.64 USD |
| Previous Close | 21.64 USD |
| Open | 21.65 USD |
| Bid | 15.6 USD x 200 |
| Ask | 27.73 USD x 200 |
| Day's Range | 21.63 - 21.76 USD |
| 52 Week Range | 6.38 - 23.57 USD |
| Volume | 35.02M USD |
| Avg. Volume | 2.18M USD |
| Market Cap | 2.12B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.71 USD |
AVDL Valuation Measures
| Enterprise Value | 2.06B USD |
| Trailing P/E | |
| Forward P/E | 27.74359 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.546691 |
| Price/Book (mrq) | 21.425743 |
| Enterprise Value/Revenue | 8.286 |
| Enterprise Value/EBITDA | 762.909 |
Trading Information
Avadel Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 162.46% |
| S&P500 52-Week Change | 32.06% |
| 52 Week High | 23.57 USD |
| 52 Week Low | 6.38 USD |
| 50-Day Moving Average | 21.52 USD |
| 200-Day Moving Average | 15.84 USD |
AVDL Share Statistics
| Avg. Volume (3 month) | 2.18M USD |
| Avg. Daily Volume (10-Days) | 4.62M USD |
| Shares Outstanding | 98.15M |
| Float | 91.56M |
| Short Ratio | 1.6 |
| % Held by Insiders | 1.12% |
| % Held by Institutions | 86.80% |
| Shares Short | 2.31M |
| Short % of Float | 2.38% |
| Short % of Shares Outstanding | 2.35% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -0.11% |
| Operating Margin (ttm) | 2.50% |
| Gross Margin | 94.91% |
| EBITDA Margin | 1.08% |
Management Effectiveness
| Return on Assets (ttm) | -0.34% |
| Return on Equity (ttm) | -0.32% |
Income Statement
| Revenue (ttm) | 248.52M USD |
| Revenue Per Share (ttm) | 2.57 USD |
| Quarterly Revenue Growth (yoy) | 54.90% |
| Gross Profit (ttm) | 235.88M USD |
| EBITDA | 2.7M USD |
| Net Income Avi to Common (ttm) | -278000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 91.58M USD |
| Total Cash Per Share (mrq) | 0.94 USD |
| Total Debt (mrq) | 37.38M USD |
| Total Debt/Equity (mrq) | 38.05 USD |
| Current Ratio (mrq) | 2.756 |
| Book Value Per Share (mrq) | 1.01 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 34.54M USD |
| Levered Free Cash Flow (ttm) | 2.73M USD |
Profile of Avadel Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | 10 Earlsfort Terrace |
| ZIP | D02 T380 |
| Phone | 353 1 901 5201 |
| Website | https://www.avadel.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 188 |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Q&A For Avadel Pharmaceuticals Stock
What is a current AVDL stock price?
Avadel Pharmaceuticals AVDL stock price today per share is 21.64 USD.
How to purchase Avadel Pharmaceuticals stock?
You can buy AVDL shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avadel Pharmaceuticals?
The stock symbol or ticker of Avadel Pharmaceuticals is AVDL.
Which industry does the Avadel Pharmaceuticals company belong to?
The Avadel Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.
How many shares does Avadel Pharmaceuticals have in circulation?
The max supply of Avadel Pharmaceuticals shares is 98.15M.
What is Avadel Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Avadel Pharmaceuticals PE Ratio is 0.00000000 now.
What was Avadel Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Avadel Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Avadel Pharmaceuticals company belong to?
The Avadel Pharmaceuticals sector is Healthcare.
Avadel Pharmaceuticals AVDL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}